Difficulty: Medium
Average Score: 95%
Practice
Hepatoblastoma is a neoplasm of undifferentiated precursors of hepatocytes. It is of different histological classification; which type predict the MOST favorable outcome?
Correct answer
B
Rationale
The correct answer is B) type of pure epithelial histology because hepatoblastomas with pure epithelial histology have been associated with the most favorable outcomes compared to other histological types. Pure epithelial hepatoblastomas typically respond better to treatment and have a higher survival rate.
Option A) mixed type of pure epithelial and mesenchymal elements is incorrect because the presence of mesenchymal elements can indicate a more aggressive tumor behavior. Option C) type of mixed fetal and embryonal histology and Option D) type of undifferentiated histology are also incorrect as they are associated with poorer prognoses and more aggressive disease progression.
In an educational context, understanding the histological classification of hepatoblastoma is crucial for pediatric oncology practitioners to make informed treatment decisions and predict patient outcomes. This question highlights the importance of recognizing the different histological types and their implications for patient management and prognosis in pediatric oncology.
Option A) mixed type of pure epithelial and mesenchymal elements is incorrect because the presence of mesenchymal elements can indicate a more aggressive tumor behavior. Option C) type of mixed fetal and embryonal histology and Option D) type of undifferentiated histology are also incorrect as they are associated with poorer prognoses and more aggressive disease progression.
In an educational context, understanding the histological classification of hepatoblastoma is crucial for pediatric oncology practitioners to make informed treatment decisions and predict patient outcomes. This question highlights the importance of recognizing the different histological types and their implications for patient management and prognosis in pediatric oncology.